Semaglutide protocol developed to address antipsychotic-induced weight gain in secure care patients

Many patients on atypical antipsychotics like clozapine experience significant weight gain, often leading to clinical obesity (BMI >35.0). This is exacerbated by drug-induced appetite promotion, apathy, and restricted physical activity, particularly in secure care settings. Current diet and exercise interventions are often insufficient. GLP-1 agonists like semaglutide offer a pharmacological adjunct for weight loss in obese adults, providing a potential solution for this challenging patient population.

This study outlines a protocol to evaluate long-term Semaglutide (Wegovy®) treatment in obese atypical antipsychotic-treated patients in a secure care setting. Patients will be selected based on NICE guidelines for weight management referral. The intervention involves weekly Semaglutide injections, combined with regular dietary advice, exercise support, and psychological support. Patient progress will be monitored for weight, activity, and diet throughout the trial duration to identify beneficiaries and inform treatment guidelines.